ArticleInternational wound journal2006
Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds.
Article in International wound journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Cytokines and Venous Leg Ulcer Healing-A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study.International wound journal · 2016Trial
- Effects of weekly LED therapy at 625 nm on the treatment of chronic lower ulcers.Lasers in medical science · 2015Trial
- Immune cells in diabetic wound repair: the key to better wound management.Frontiers of medicine · 2025Review
- Therapeutic Properties of M2 Macrophages in Chronic Wounds: An Innovative Area of Biomaterial-Assisted M2 Macrophage Targeted Therapy.Stem cell reviews and reports · 2025Review
- The gut barrier as a gatekeeper in colorectal cancer treatment.Oncotarget · 2024Review
- Monoclonal Antibodies in the Management of Inflammation in Wound Healing: An Updated Literature Review.Journal of clinical medicine · 2024Review
- Cellular therapeutics and immunotherapies in wound healing - on the pulse of time?Military Medical Research · 2024Review
- Exploring Microemulsion Systems for the Incorporation of Glucocorticoids into Bacterial Cellulose: A Novel Approach for Anti-Inflammatory Wound Dressings.Pharmaceutics · 2024Article
- Targeting Grancalcin Accelerates Wound Healing by Improving Angiogenesis in Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The biological and physiological impact of the performance of wound dressings.International wound journal · 2023Review
- Macrophages in Skin Wounds: Functions and Therapeutic Potential.Biomolecules · 2022Review
- Macrophages as a therapeutic target to promote diabetic wound healing.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Topical gel-based biomaterials for the treatment of diabetic foot ulcers.Acta biomaterialia · 2022Review
- Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Article
- Topical Sevoflurane: A Novel Treatment for Chronic Pain Caused by Venous Stasis Ulcers.Anesthesiology and pain medicine · 2021Review
- On-demand and tunable dual wavelength release of antibody using light-responsive hydrogels.ACS applied bio materials · 2020Article
- Proinflammatory cytokines regulate epidermal stem cells in wound epithelialization.Stem cell research & therapy · 2020Review
- Article
- Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case.International wound journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of tumour necrosis factor-alpha (TNF-alpha) in wound healing is not clear. Elevated levels of TNF-alpha have been observed in fluids from chronic wounds and have been shown to decrease over time during the healing process. Therapeutic antibodies such as infliximab can inhibit TNF-alpha activity. In this case series, we applied infliximab topically to eight patients with chronic ulcers of more than 4-month durations. The ulcers had multifactorial aetiology, with chronic venous insufficiency being the most prominent factor. All the ulcers had failed to respond to any previous conventional treatment. Infliximab was applied repeatedly to ulcers either as a 10 mg/ml solution and covered with an adhesive sheet or as a gel formulation (0.45, 1, or 4.5 mg/g) under a hydrofiber dressing/adhesive sheet. Improvement was assessed by measuring the percentage of change in the ulcer surface area. Seven of the eight patients (12 of 14 ulcers) responded to treatment with infliximab. After 4 weeks of treatment, surface area was reduced by more than 50% in 6 of the 14 treated ulcers. Within 8 weeks, five ulcers completely healed, while another four were reduced by more than 75% in size. Chronic, therapy-resistant leg ulcers responded well to repeated topical administration of a solution or a gel containing the TNF-alpha antibody, infliximab. Randomised controlled studies should be conducted to further evaluate the effect of topical infliximab on chronic wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.